Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Canertinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 20/20 | 0.97 |
| ▸ | ERBB2 known ✓ | P04626 | 9/20 | 0.97 |
| ▸ | ERBB4 known ✓ | Q15303 | 3/20 | 0.97 |
| ▸ | KIT | P10721 | 2/20 | 0.97 |
| ▸ | SRC | P12931 | 2/20 | 0.97 |
| ▸ | ERBB3 | P21860 | 2/20 | 0.97 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.97 |
| ▸ | CIT | O14578 | 1/20 | 0.97 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.97 |
| ▸ | GAK | O14976 | 1/20 | 0.97 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.97 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.97 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.97 |
| ▸ | STK17B | O94768 | 1/20 | 0.97 |
| ▸ | STK10 | O94804 | 1/20 | 0.97 |
| ▸ | ABL1 | P00519 | 1/20 | 0.97 |
| ▸ | LCK | P06239 | 1/20 | 0.97 |
| ▸ | FYN | P06241 | 1/20 | 0.97 |
| ▸ | YES1 | P07947 | 1/20 | 0.97 |
| ▸ | LYN | P07948 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Canertinib SCHEMBL29655741 | 0.99 | EGFR (1.00) | EGFRERBB2ERBB4KITSRC | |
| Canertinib SCHEMBL54837 | 0.99 | EGFR (1.00) | EGFRERBB2ERBB4KITSRC | |
| Canertinib SCHEMBL29368458 | 0.99 | EGFR (1.00) | EGFRERBB2ERBB4KITSRC | |
| Canertinib SCHEMBL29623482 | 0.99 | EGFR (1.00) | EGFRERBB2ERBB4KITSRC | |
| Canertinib SCHEMBL2052123 | 0.98 | EGFR (1.00) | EGFRERBB2ERBB4KITSRC | |
| Canertinib SCHEMBL30436576 | 0.98 | EGFR (1.00) | EGFRERBB2ERBB4KITSRC | |
| Canertinib SCHEMBL2141065 | 0.98 | EGFR (1.00) | EGFRERBB2ERBB4KITSRC | |
| SCHEMBL3585133 | 0.92 | EGFR (0.88) | EGFRERBB2ERBB4KITSRC | |
| SCHEMBL30415948 | 0.92 | EGFR (0.88) | EGFRERBB2ERBB4KITSRC | |
| SCHEMBL13153156 | 0.91 | EGFR (0.86) | EGFRERBB2ERBB4KITSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240139315-A1 | COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF HEARING LOSS | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. | 2024-05-02 | — | — | US | disclosed |
| CN-111655228-B | Compositions and methods for preventing and treating hearing loss | 听治疗有限责任公司 | 2024-02-09 | — | — | CN | disclosed |
| US-11883491-B2 | Compositions and methods for prevention and treatment of hearing loss | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. (US) | 2024-01-30 | — | — | US | disclosed |
| US-20240016840-A1 | METHODS AND COMPOSITIONS FOR USE OF THERAPEUTIC T CELLS IN COMBINATION WITH KINASE INHIBITORS | JUNO THERAPEUTICS, INC. (US) | 2024-01-18 | — | — | US | disclosed |
| US-11590167-B2 | Methods and compositions for use of therapeutic T cells in combination with kinase inhibitors | Juno Therapeutic, Inc. (US) | 2023-02-28 | — | — | US | disclosed |
| CN-114981298-A | Compositions and methods for preventing and treating hearing loss | 听治疗有限责任公司 | 2022-08-30 | — | — | CN | disclosed |
| US-20220133730-A1 | Compositions and Methods for the Prevention and Treatment of Hearing Loss | TING THERAPEUTICS LLC (US) | 2022-05-05 | — | — | US | disclosed |
| CN-111655228-A | Compositions and methods for preventing and treating hearing loss | J·左 | 2020-09-11 | — | — | CN | disclosed |
| US-20200093923-A1 | COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF HEARING LOSS | ST. JUDE CHILDREN'S RESEARCH HOSPITALEINDHOVEN (US) | 2020-03-26 | — | — | US | disclosed |
| EP-3618807-A1 | COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF HEARING LOSS | Zuo, Jian (US) | 2020-03-11 | — | — | EP | disclosed |
| US-20090170783-A1 | NOVEL TETRAHYDROCARBAZOLE DERIVATIVES AS LIGANDS OF G-PROTEIN COUPLED RECEPTORS | AETERNA ZENTARIS GMBH (DE) | 2009-07-02 | — | — | US | disclosed |
| CN-101415440-A | Method for treating lung cancer | UNIV TOKYO (JP) | 2009-04-22 | — | — | CN | disclosed |
| EP-2021502-A1 | NOVEL GENES AND MARKERS IN TYPE 2 DIABETES AND OBESITY | Oy Jurilab Ltd (FI) | 2009-02-11 | — | — | EP | disclosed |
| WO-2008132153-A1 | NOVEL TETRAHYDROCARBAZOLE DERIVATIVES AS LIGANDS OF G-PROTEIN COUPLED RECEPTORS | ÆTERNA ZENTARIS GMBH (DE) | 2008-11-06 | — | — | WO | disclosed |
| EP-1988098-A1 | Novel Tetrahydrocarbazole Derivatives as Ligands of G-protein Coupled Receptors | AEterna Zentaris GmbH (DE) | 2008-11-05 | — | — | EP | disclosed |
| EP-1978930-A2 | SUTURES AND ANTI-SCARRING AGENTS | Angiotech Pharmaceuticals, Inc. (CA) | 2008-10-15 | — | — | EP | disclosed |
| WO-2007128884-A1 | NOVEL GENES AND MARKERS IN TYPE 2 DIABETES AND OBESITY | OY JURILAB LTD (FI) | 2007-11-15 | — | — | WO | disclosed |
| WO-2007089878-A2 | SUTURES AND ANTI-SCARRING AGENTS | ANGIOTECH PHARMACEUTICALS, INC. (CA) | 2007-08-09 | — | — | WO | disclosed |
| WO-2006121522-A2 | IMPLANTABLE SENSORS AND PUMPS, ANTI-SCARRING AGENTS, AND THERAPEUTIC COMPOSITIONS | ANGIOTECH INTERNATIONAL AG (CH) | 2006-11-16 | — | — | WO | disclosed |
| WO-2006121518-A2 | ELECTRICAL DEVICES, ANTI-SCARRING AGENTS, AND THERAPEUTIC COMPOSITIONS | ANGIOTECH INTERNATIONAL AG (CH) | 2006-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240016840-A1 | METHODS AND COMPOSITIONS FOR USE OF THERAPEUTIC T CELLS IN COMBINATION WITH KINASE INHIBITORS | ITK, PBK, BMX | EGFR 37/4885ERBB2 13/4885ERBB4 12/4885 |
| US-20090170783-A1 | NOVEL TETRAHYDROCARBAZOLE DERIVATIVES AS LIGANDS OF G-PROTEIN COUPLED RECEPTORS | GPR88, GPR34, GPR27 | EGFR 1394/4885ERBB2 829/4885ERBB4 526/4885 |
| US-11590167-B2 | Methods and compositions for use of therapeutic T cells in combination with kinase inhibitors | ITK, PBK, BMX | EGFR 30/4885ERBB2 11/4885ERBB4 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.